Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Albuterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 10/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albuterol SCHEMBL2489838 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL5881204 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29361075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL122805 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL4003 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL121596 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL4913 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL29496690 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL28434340 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29620266 | 0.98 | TDP1 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 432 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119019271-A | Synthesis method of free racemic salbutamol | 武汉武药制药有限公司 | 2024-11-26 | — | — | CN | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | claimed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | claimed |
| EP-3910881-B1 | QOE ASSESSMENT METHOD AND RELATED DEVICE | HUAWEI TECH CO LTD (CN) | 2023-07-26 | — | — | EP | claimed |
| CN-112592280-B | Preparation method of racemic salbutamol | 青岛职业技术学院 | 2023-05-23 | — | — | CN | claimed |
| US-20220362174-A1 | Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effects | TAN WEN (CN) | 2022-11-17 | — | — | US | claimed |
| CN-109678707-B | Deuterium labeled D3Synthesis method of (E) -salbutamol | 东莞暨南大学研究院 | 2022-05-06 | — | — | CN | claimed |
| CN-114200053-A | Method for simultaneously detecting residues of various veterinary drugs in biogas slurry | 碳元复兴(厦门)科技有限公司 | 2022-03-18 | — | — | CN | claimed |
| CN-113960194-A | Method for simultaneously determining contents of multiple food-borne stimulants in livestock and poultry meat | 北京市科学技术研究院分析测试研究所(北京市理化分析测试中心) | 2022-01-21 | — | — | CN | claimed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | claimed |
| WO-2015029072-A2 | RACEMIC DRUG RESOLUTION USING POLYMER SUPPORTED CHIRAL SELECTOR | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-03-05 | — | — | WO | claimed |
| WO-2014028796-A2 | PREPARATION OF DESICCATED LIPOSOMES FOR USE IN COMPRESSIBLE DELIVERY SYSTEMS | SMARTEK INTERNATIONAL LLC (US) | 2014-02-20 | — | — | WO | claimed |
| EP-0308157-A2 | Therapeutic applications of beta-adrenergic agonists | The Rowett Research Institute (GB) | 1989-03-22 | — | — | EP | claimed |
| EP-0272393-A2 | Pharmaceutical combination | Euro-Celtique S.A. (LU) | 1988-06-29 | — | — | EP | claimed |
| US-4484577-A | Drug delivery method and inhalation device therefor | KEY PHARMACEUTICALS, INC. (US) | 1984-11-27 | — | — | US | claimed |
| EP-0108145-A4 | DEVICE FOR DELIVERY OF A DRUG. | KEY PHARMA (US) | 1984-09-28 | — | — | EP | claimed |
| EP-0108145-A1 | DEVICE FOR DELIVERY OF A DRUG. | KEY PHARMA (US) | 1984-05-16 | — | — | EP | claimed |
| WO-1983003976-A1 | DEVICE AND METHOD FOR DELIVERY OF A DRUG | KEY PHARMACEUTICALS, INC. (US) | 1983-11-24 | — | — | WO | claimed |
| US-4153677-A | MICROENCAPSULATED BRONCHODILATOR AGENT, ETHYL CELLULOSE FILM | STERLING DRUG INC. (US) | 1979-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885CYP1A2 37/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885CYP1A2 37/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885CYP1A2 37/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | ADRB2 591/4885ADRB1 445/4885CYP1A2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.